Duke-NUS
8 College Road, Singapore, Central Singapore, 169857, Singapore
Overview
Collaboration between Duke University and National University of Singapore. Duke-NUS follows the American model of post-baccalaureate medical education in which students begin their medical studies after earning a bachelor's degree. Offers MD, MD/PhD and PhD programs. Duke-NUS aim to develop students to become medical doctors and medical researchers. Creativity, critical thinking and teamwork are important values that are imparted to our students - that will help them to change and improve the practice of medicine.
- Total investments
- 1
- Lead investments
- 0
- Investments · 12mo
- 1
- Active investors
- 8
Sector focus
- Universities
Investment portfolio
- Brano Therapeutics
Participated · Seed · May 2026
Brano Therapeutics is developing small-molecule therapies that target a metabolic abnormality implicated in heart failure with preserved ejection fraction (HFpEF). Its research is based on discoveries by Duke-NUS scientists and collaborators such as the University of Cincinnati, which suggest impaired nutrient processing in the heart contributes to disease progression. Preclinical studies reportedly show a compound can help restore metabolic regulation, reduce heart stiffness, and improve function. The company has a licensing agreement with Duke-NUS to advance these discoveries toward clinical application. Brano plans to develop new compounds and move its lead therapies into clinical trials by 2029. Financially, the company completed a $6.8 million seed round to fund these development activities.